Research.Patient.info
Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers) research hub
2 indexed studies · 0 currently recruiting
- ongoing, recruitingTherapeutic exploratory (Phase II)
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice (IC) Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)
This study is for women with advanced ovarian (or related) cancer that has come back and isn't responding to platinum-based chemotherapy. Researchers are comparing a new treatment called Luveltamab Tazevibulin with standard chemotherapy to see if it works better and is safe.
Austria · Finland · Czechia - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
This study is testing a new medicine called STRO-002, given with another medicine called bevacizumab. It's for women with advanced ovarian cancer (including fallopian tube or primary peritoneal cancers) to see if it's safe and how it works in the body.
France · Italy · Spain